BPC-157
These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.
What the opened sources say
Section titled “What the opened sources say”- On the compounding-risk page, BPC-157 is under “Bulk drug substances nominated but withdrawn,” not in the table of substances still in Category 2. FDA says nominations on that withdrawn list were previously in Category 2 and were withdrawn by the nominators.
- FDA’s text for BPC-157 says compounded drugs containing it may pose an immunogenicity risk for certain routes, may be hard to characterize, and that FDA has no or only limited safety information for the proposed routes, so it cannot tell whether the drug would cause harm.
- The 23 July 2026 PCAC agenda says the committee would discuss BPC-157 free base and BPC-157 acetate for the 503A bulks list. The use FDA says it evaluated is ulcerative colitis. This page does not report a vote.
Not stated here
Section titled “Not stated here”Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (primary, accessed 2026-11-20)
Referenced by
- CJC-1295
- FDA Category 2 and withdrawn nominations
- GHK-Cu
- Ipamorelin
- Melanotan II
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Peptides
- TB-500
A link from another wiki page is not evidence. Facts should point at the sources above.